

1 Concurrent human antibody and T_H1 type T-cell responses 2 elicited by a COVID-19 RNA vaccine

3
4 Ugur Sahin^{1,2}, Alexander Muik¹, Evelyn Derhovanessian¹, Isabel Vogler¹, Lena M. Kranz¹, Mathias
5 Vormehr¹, Alina Baum⁴, Kristen Pascal⁴, Jasmin Quandt¹, Daniel Maurus¹, Sebastian Brachtendorf¹,
6 Verena Lörks¹, Julian Sikorski¹, Rolf Hilker¹, Dirk Becker¹, Ann-Kathrin Eller¹, Jan Grützner¹, Carsten
7 Boesler¹, Corinna Rosenbaum¹, Marie-Cristine Kühnle¹, Ulrich Luxemburger¹, Alexandra Kemmer-
8 Brück¹, David Langer¹, Martin Bexon⁷, Stefanie Bolte¹, Katalin Karikó¹, Tania Palanche¹, Boris
9 Fischer¹, Armin Schultz⁶, Pei-Yong Shi⁵, Camila Fontes-Garfias⁵, John L. Perez³, Kena A. Swanson³,
10 Jakob Loschko³, Ingrid L. Scully³, Mark Cutler³, Warren Kalina³, Christos A. Kyratsous⁴, David
11 Cooper³, Philip R. Dormitzer³, Kathrin U. Jansen³, Özlem Türeci¹

12
13 ¹ BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.

14 ² TRON gGmbH – Translational Oncology at the University Medical Center of the Johannes Gutenberg,
15 University Freiligrathstraße 12, 55131 Mainz, Germany.

16 ³ Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.

17 ⁴ Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY 10591, U.S.A.

18 ⁵ University of Texas Medical Branch, Galveston, TX 77555, U.S.A.

19 ⁶ CRS Clinical Research Services Mannheim GmbH, Grenadierstrasse 1, 68167 Mannheim, Germany

20 ⁷ Bexon Clinical Consulting LLC, Upper Montclair, NJ 07043, U.S.A.

21
22 **Correspondence:** Ugur Sahin, BioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany, Tel: +49
23 6131 9084 1801, Email: Ugur.Sahin@biontech.de

24
25
26 An effective vaccine is needed to halt the spread of the SARS-CoV-2 pandemic. Recently, we reported
27 safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded
28 phase 1/2 COVID-19 vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-
29 modified messenger RNA encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike
30 protein. Here we present antibody and T cell responses after BNT162b1 vaccination from a second, non-
31 randomized open-label phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 µg of
32 BNT162b1 elicited robust CD4⁺ and CD8⁺ T cell responses and strong antibody responses, with RBD-
33 binding IgG concentrations clearly above those in a COVID-19 convalescent human serum panel (HCS).
34 Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 µg) to 3.5-fold (50 µg)
35 those of HCS. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants.
36 Most participants had T_H1 skewed T cell immune responses with RBD-specific CD8⁺ and CD4⁺ T cell
37 expansion. Interferon (IFN)γ was produced by a high fraction of RBD-specific CD8⁺ and CD4⁺ T cells.
38 The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1
39 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 **Main**

41 **Introduction**

42 In December 2019, the novel coronavirus SARS-CoV-2 emerged in China causing coronavirus disease
43 2019 (COVID-19), a severe, acute respiratory syndrome with a complex, highly variable disease
44 pathology. On 11 March 2020, the World Health Organization (WHO) declared the SARS-CoV-2
45 outbreak a pandemic. As of 29 June 2020, over 10 million cases have been reported worldwide, with
46 deaths approaching half a million¹.

47 The high and worldwide impact on human society calls for the rapid development of safe and effective
48 therapeutics and vaccines².

49 Messenger RNA (mRNA) vaccine technology allows to deliver precise genetic information encoding a
50 viral antigen together with intrinsic adjuvant effect to antigen presenting cells³. The prophylactic
51 effectiveness of this technology has been proven in preclinical models against multiple viral targets⁴⁻⁶.
52 LNP- and liposome-formulated RNA vaccines for prevention of infectious diseases and for treatment of
53 cancer have been shown in clinical trials to be safe and well-tolerated⁷. mRNA is transiently expressed
54 and does not integrate into the genome. It is molecularly well defined, free of animal-origin materials
55 and synthesized by an efficient, cell-free *in vitro* transcription process from DNA templates^{4,8,9}. The fast
56 and highly scalable mRNA manufacturing and lipid-nanoparticle (LNP) formulation processes enable
57 rapid production of many vaccine doses^{5,6,10}, making it suitable for rapid vaccine development and
58 pandemic vaccine supply.

59 Two Phase 1/2 umbrella trials in Germany and the US investigate several LNP-encapsulated RNA
60 vaccine candidates developed in `Project Lightspeed`. Recently, we have reported interim data obtained
61 in the US trial (NCT04368728) for the most advanced candidate BNT162b1¹¹. BNT162b1 encodes the
62 receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, a key target of neutralising
63 antibodies. The RBD antigen expressed by BNT162b1 is fused to a T4 fibritin-derived “foldon”
64 trimerisation domain to increase its immunogenicity by multivalent display¹². The RNA is optimized
65 for high stability and translation efficiency^{13,14} and incorporates 1-methyl-pseudouridine instead of
66 uridine to dampen innate immune sensing and to increase mRNA translation *in vivo*¹⁵. In the placebo-
67 controlled, observer-blinded US trial, dosages of 10 µg, 30 µg (prime and boost doses 21 days apart for
68 both dose levels) and 100 µg (prime only) were administered. No serious adverse events were reported.
69 Local injection site reactions and systemic events (mostly flu-like symptoms) were dose-dependent,
70 generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2
71 neutralising titers in sera increased with dose level and after a second dose. Fourteen days after the boost,
72 geometric mean neutralising titers reached 1.9- to 4.6-fold of a panel of COVID-19 convalescent human
73 sera.

74 This study now complements our previous report with available data from the German trial
75 (NCT04380701, EudraCT: 2020-001038-36), providing a detailed characterisation of antibody and T-
76 cell immune responses elicited by BNT162b1 vaccination.

77

78 **Results**

79 **Study design and analysis set**

80 Between 23 April 2020 and 22 May 2020, 60 participants were vaccinated with BNT162b1 in Germany.
81 Twelve participants per 1 µg, 10 µg, 30 µg, and 50 µg dose level groups received a first dose on Day 1
82 and were boosted on Day 22 (except for one individual each in the 10 and 50 µg dose-level cohort who
83 discontinued due to non-study drug related reasons), and 12 participants received a 60 µg prime dose on
84 Day 1 only (Extended Data Figure 1). The study population consisted of healthy males and non-pregnant
85 females with a mean age of 41 years (range 18 to 55 years) with equal gender distribution. Most
86 participants were Caucasian (96.7%) with one African American and one Asian participant (1.7% each).
87 Preliminary data analysis focused on immunogenicity (Extended Data Table 1).

88 **Preliminary available safety and tolerability data**

89 Briefly, no serious adverse events (SAE) and no withdrawals due to related adverse events (AEs) were
90 observed for any dose. Similar to the U.S. trial, most reported solicited events in the 10 µg and 30 µg
91 groups were reactogenicity (*e.g.*, fatigue and headache), with a typical onset within the first 24 hours
92 after immunisation. Injection site reactions within 7 days of the prime or boost were mainly pain and
93 tenderness (Extended Data Figure 2). Symptomatology was mostly mild or moderate with occasional
94 severe (Grade 3) reactogenicity such as fever, chills, headache, muscle pain, joint pain, injection site
95 pain, and tenderness within 7 days after each dose. Reactogenicity resolved spontaneously, or could be
96 managed with simple measures (*e.g.* paracetamol). Based on the reactogenicity reported after the 50 µg
97 boost dose, a second 60 µg dose was not administered to participants who had received an initial 60 µg
98 dose.

99 Whereas no relevant change in routine clinical laboratory values occurred after BNT162b1 vaccination,
100 a transient increase in C-reactive protein (CRP) and temporary reduction of blood lymphocyte counts
101 were observed in a dose-dependent manner in vaccinated participants (Extended Data Figure 3). CRP is
102 a well-known inflammatory serum protein previously described as biomarker for various infectious
103 disease vaccines and an indicator of vaccine adjuvant activity¹⁶⁻¹⁹. Based on our previous clinical
104 experience with RNA vaccines the transient decrease in lymphocytes is likely attributable to innate
105 immune stimulation-related redistribution of lymphocytes into lymphoid tissues²⁰. Both parameters are
106 considered pharmacodynamics markers for the mode-of-action of RNA vaccines.

107

108 **Vaccine-induced antibody response**

109 RBD-binding IgG concentrations and SARS-CoV-2 neutralising titers were assessed at baseline, 7 and
110 21 days after the BNT162b1 priming dose (Days 8 and 22), and 7 and 21 days after the boosting dose
111 (Days 29 and 43), except for the 60 µg cohort, which received a priming dose only (Figure 1).

112 Immunised participants showed a strong, dose-dependent vaccine-induced antibody response. Twenty-
113 one days after the priming dose (for the four dose levels ranging from 1-50 µg), geometric mean
114 concentrations (GMCs) of RBD-binding IgG had increased in a dose level dependent manner, with
115 GMCs ranging from 265-1,672 U/mL (Figure 1). Seven days after the boosting dose (Day 29), RBD-
116 binding IgG GMCs in participants vaccinated with 1-50 µg BNT162b1 showed a strong, dose-level
117 dependent booster response ranging from 2,015-25,006 U/mL. At Day 43 (21 days after boost), RBD-
118 binding antibody GMCs were in the range of 3,920-18,289 U/mL in BNT162b1 vaccinated individuals
119 as compared to a GMC of 602 U/mL measured in a panel of convalescent sera from 38 SARS-CoV-2
120 infection patients. The patients were 18-83 years of age, and sera were drawn at least 14 days after PCR-
121 confirmed diagnosis. In the 60 µg dose-level cohort, which received a priming dose only, RBD-binding
122 IgG GMCs were 1,058 U/mL by Day 29, indicating that a boosting dose to increase antibody titers may
123 be necessary.

124 SARS-CoV-2 neutralising antibody geometric mean titers (GMTs) increased modestly in a dose-
125 dependent manner 21 days after the priming dose (Figure 2a). Substantially higher serum-neutralising
126 GMTs were achieved 7 days after the booster dose, reaching 36 (1 µg dose level), 158 (10 µg dose
127 level), 308 (30 µg dose level), and 578 (50 µg dose level), compared to 94 for the convalescent serum
128 panel. On Day 43 (21 days after the boost), the neutralising GMTs decreased (with exception of the 1 µg
129 dose level). Neutralising antibody GMTs were strongly correlated with RBD-binding IgG GMC
130 (Figure 2b). In summary, antibody responses elicited by BNT162b1 in study BNT162-01 largely
131 mirrored those observed in the U.S. study¹¹.

132 To demonstrate the breadth of the neutralising response, a panel of 16 SARS-CoV-2 RBD variants
133 identified through publicly available information²¹ and the dominant (non-RBD) spike variant D614G²²
134 was evaluated in pseudovirion neutralisation assays. Sera collected 7 days after the second dose of
135 BNT162b1 showed high neutralising titers to each of the SARS-CoV-2 spike variants (Figure 2c).

136 **Vaccine-induced T cell responses**

137 CD4⁺ and CD8⁺ T cell responses in BNT162b1 immunised participants were characterised prior to
138 priming vaccination (Day 1) and 7 days after boost vaccination (on Day 29) using direct *ex vivo* IFNγ
139 ELISpot with peripheral blood mononuclear cells (PBMCs) from 36 participants across the 1 µg to
140 50 µg dose-level cohorts (Figure 3). In this assay, CD4⁺ or CD8⁺ T cell effectors were stimulated
141 overnight with overlapping peptides representing the full-length sequence of the vaccine-encoded RBD.

142 Of 36 participants, 34 (94.4%, including all participants treated with $\geq 10 \mu\text{g}$ BNT162b1) mounted RBD-
143 specific CD4⁺ T cell responses. While the magnitude varied between individuals, participants with the
144 strongest CD4⁺ T cell responses to RBD had more than 10-fold of the memory responses observed in
145 the same participants when stimulated with cytomegalovirus (CMV), Epstein Barr virus (EBV),
146 influenza virus and tetanus toxoid-derived immuno-dominant peptide panels (Figure 3a-c). No CD4⁺ T
147 cell responses were detectable at baseline, except for one participant with a low number of preexisting
148 RBD-reactive CD4⁺ T cells, which increased significantly after vaccination (normalised mean spot count
149 from 63 to 1,519, in the 50 μg dose cohort). The strength of RBD-specific CD4⁺ T cell responses
150 correlated positively with both RBD-binding IgG and with SARS-CoV-2 neutralising antibody titers
151 (Extended Data Figure 4a, d), in line with the concept of intramolecular help²³. The two participants
152 lacking CD4⁺ response had no detectable virus neutralising titers (VNT₅₀) (Extended Data Figure 4d).

153 Among vaccine-induced CD8⁺ T cell responses (29/36 participants, 80.6%), strong responses were
154 mounted by the majority of participants (Figure 3a) and were quite comparable with memory responses
155 against CMV, EBV, influenza virus and tetanus toxoid in the same participants (Figure 3b, c). The
156 strength of RBD-specific CD8⁺ T cell responses correlated positively with vaccine-induced CD4⁺ T cell
157 responses, but did not significantly correlate with SARS-CoV-2 neutralising antibody titers (Extended
158 Data Figure 4b, c).

159 Of note, although at 1 μg BNT162b1 the immunogenicity rate was lower (6/8 responding participants),
160 the magnitude of vaccine-induced CD4⁺ and CD8⁺ T cells in some participants was almost as high as
161 with 50 μg BNT162b1 (Figure 3a). To assess functionality and polarisation of RBD-specific T cells,
162 cytokines secreted in response to stimulation with overlapping peptides representing the full length
163 sequence of the vaccine encoded RBD were determined by intracellular staining (ICS) for IFN γ , IL-2
164 and IL-4 specific responses in pre- and post-vaccination PBMCs of 18 BNT162b1 immunised
165 participants. RBD-specific CD4⁺ T cells secreted IFN γ , IL-2, or both, but did not secrete IL-4 (Figure 4
166 a-c). Similarly, fractions of RBD-specific CD8⁺ T cells secreted IFN γ and IL-2.

167 The mean fraction of RBD-specific T cells within total circulating T cells obtained by BNT162b1
168 vaccination was substantially higher than that observed in six participants who recovered from COVID-
169 19. Fractions of RBD-specific IFN γ ⁺ CD8⁺ T cells reached up to several percent of total peripheral blood
170 CD8⁺ T cells (Figure 4c). Analysis of supernatants of PBMCs stimulated *ex vivo* with overlapping RBD
171 peptides from a subgroup of five vaccinated participants detected proinflammatory cytokines TNF, IL-
172 1 β and IL-12p70, but neither IL-4 nor IL-5 (Figure 4d).

173 In summary, these findings indicate that BNT162b1 induces functional and proinflammatory
174 CD4⁺/CD8⁺ T cell responses in almost all participants, with T_H1 polarisation of the helper response.

175

176 Discussion

177 We observed concurrent production of neutralising antibodies, activation of virus-specific CD4⁺ and
178 CD8⁺ T cells, and robust release of immune-modulatory cytokines such as IFN γ , which represents a
179 coordinated immune response to counter a viral intrusion (for review ²⁴). IFN γ is a key cytokine for
180 several antiviral responses. It acts in synergy with type I interferons to inhibit replication of SARS-CoV-
181 2²⁵. Patients with IFN γ gene polymorphism related to impaired IFN γ activity have been shown to display
182 5-fold increased susceptibility to SARS²⁶. The robust production of IFN γ from CD8⁺ T cells indicates a
183 favourable immune response with both anti-viral and immune-augmenting properties.

184 The detection of IFN γ , IL-2 and IL-12p70 but not IL-4 indicates a favorable T_H1 profile and the absence
185 of a potentially deleterious T_H2 immune response. CD4⁺ and CD8⁺ T cells may confer long-lasting
186 immunity against corona viruses as indicated in SARS-CoV-1 survivors, where CD8⁺ T-cell immunity
187 persisted for 6-11 years^{24,27}.

188 Some cases of asymptomatic virus exposure have been associated with cellular immune response
189 without seroconversion indicating that SARS-CoV-2 specific T cells could be relevant in disease control
190 even in the absence of neutralising antibodies²⁸. Almost all vaccinated volunteers mounted RBD-specific
191 T cell responses detected with an *ex vivo* ELISpot assay, which was performed without prior expansion
192 of T cells that captures only high-magnitude T cell responses. Although the strength of the T-cell
193 responses varied considerably between participants, we observed no clear dose dependency of the T-
194 cell response strength using vaccine dose levels of 1 μ g to 50 μ g, indicating that stimulation and robust
195 expansion of T cells might be accomplished at the lowest mRNA-encoded immunogen levels.

196 The study confirms the dose-dependency of RBD-binding IgG and neutralisation responses and
197 reproduces our previous findings for the 10 and 30 μ g dose levels of BNT162b1 in the US trial.

198 A notable observation is that two injections of BNT162b1 at a dose level as low as 1 μ g are capable of
199 inducing RBD-binding IgG levels higher than those observed in convalescent sera, and serum
200 neutralising antibody titers that were still increasing up to Day 43. Considering that it is not known
201 which neutralising antibody titer would be protective, and given the substantial T-cell responses we
202 observed for some participants in the 1 μ g cohort, a considerable fraction of individuals may benefit
203 even from this lowest tested dose level.

204 A purely RBD-directed immunity might be considered prone to escape of the virus by single amino acid
205 changes in this small domain. To address this concern, neutralisation assays were conducted with 17
206 pseudo-typed viruses, 16 of which enter cells using a spike with a different RBD variant found in
207 circulating strains and one of which uses the dominant spike variant D614G. All 17 variants were
208 efficiently neutralised by BNT162b1 immune sera.

209 Limitations of our clinical study include the small sample size and its restriction to participants below
210 55 years of age. Another constraint is that we did not perform further T cell analysis *e.g.* deconvolution

211 of epitope diversity, characterisation of HLA restriction and TCR repertoire analysis before and after
212 vaccination, due to the limited blood volumes that were available for biomarker analyses. Further, as
213 vaccine-induced immunity can wane over time, it is important to study persistence of potentially
214 protective immune responses over time. However, samples to assess persistence are not yet available
215 but are planned per study protocol and will be reported elsewhere.

216 **Acknowledgements**

217 We thank Mikael Dolsten, Pfizer Chief Scientific Officer, for advice during drafting of the manuscript.
218 We thank C. Anders, C. Anft, N. Beckmann, K. Bissinger, G. Boros, P. Cienskowski, K. Clarke, C.
219 Ecker, A. Engelmann, Y. Feuchter, L. Heesen, M. Hossainzadeh, S. Jäggle, L. Jeck, O. Kahl, M.
220 Knezovic, T. Kotur, M. Kretschmer, O. Pfante, J. Reinholz, L.-M. Schmid, R. Schulz, B. Stock, C.
221 Müller, S. Murphy, G. Szabó and M. Vehreschild for technical support, project management and advice,
222 and A. Finlayson and M. Rao for providing editorial assistance. We thank P. Koch and F. Groher for
223 data management and analysis. We thank S. Liebscher and O. Kistner for expert advice. We thank Judith
224 Absalon for manuscript advice. We thank the CRS Team (Mannheim and Berlin) for study conduct: S.
225 Baumann, M. Berse, M. Casjens, B. Ehrlich, F. Seitz. We thank the Pfizer Vaccines Clinical Assays
226 Team and the Pfizer Aviation Team for technical and logistical support of serology analyses.

227 **Author Contributions**

228 U.S. conceived and conceptualised the work and strategy supported by Ö.T. Experiments were planned
229 or supervised by E.D., C. F.-G, C.A.K., L.M.K., U.L., A.M., J.Q., P.-Y.S., and I.V.. A.B., D.C, M.C.,
230 C. F.-G, W.K., K.P., J.Q., I.S. and P.-Y.S. performed experiments. D.B., S.B., E.D., P.R.D., J.G., K.U.J.,
231 A.-K.E., L.M.K., M.-C.K., V.L., A.M., J.Q., J.S., I.V. and M.V. analysed data. D.M. planned and
232 supervised dashboards for analysis of clinical trial data. R.H. was responsible for data normalization and
233 adaption. C.B. and C.R. were responsible for biomarker and R&D program management. K.K.
234 optimized the mRNA. M.B., S.B., B.F., A.K.-B., D.L. and T.P., A.S., coordinated operational conduct
235 of the clinical trial. J.L.P. advised on the trial, and J.L. and K.A.S advised on experiments. U.S., Ö.T.,
236 supported by M.B., E.D., P.R.D., K.U.J., L.M.K., A.M., I.V. and M.V., interpreted data and wrote the
237 manuscript. All authors supported the review of the manuscript.

238 **Competing interests**

239 All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf
240 and declare: U.S. and Ö.T. are management board members and employees at BioNTech SE (Mainz,
241 Germany); D.B., C.B., S.B., E.D., A.-K.E., B.F., J.G., R.H., M.-C.K., U.L., V.L., D.M., C.R., J.S. and
242 T.P. are employees at BioNTech SE; K.K., L.M.K., I.V., A.M., J.Q. and M.V. are employees at
243 BioNTech RNA Pharmaceuticals GmbH; M.B. is an employee at Bexon Clinical Consulting LLC. A.B.,
244 C.A.K. and K.P. are employees of Regeneron Pharmaceuticals Inc; K.K., A.M., U.S. and Ö.T. are
245 inventors on patents and patent applications related to RNA technology and COVID-19 vaccine; D.B.,
246 C.B., S.B., E.D., J.G., K.K., R.H., A.K.-B., L.M.K., D.L., U.L., A.M., C.R., U.S., Ö.T., I.V. and M.V.
247 have securities from BioNTech SE; D.C., M.C., P.R.D., K.U.J., W.K., J.L., J.L.P., I.L.S. and K.A.S.

248 are employees at Pfizer and may have securities from Pfizer; C.A.K. is an officer at Regeneron
249 Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from Regeneron Pharmaceuticals, Inc; C.F.-
250 G. and P.-Y.S. received compensation from Pfizer to perform the neutralisation assay; no other
251 relationships or activities that could appear to have influenced the submitted work.

252 **Funding**

253 BioNTech is the Sponsor of the study and responsible for the design, data collection, data analysis, data
254 interpretation, and writing of the report. Pfizer advised on the study and the manuscript, generated
255 serological data, and contracted for the generation of serological data. The corresponding authors had
256 full access to all the data in the study and had final responsibility for the decision to submit the data for
257 publication. All study data were available to all authors. This study was not supported by any external
258 funding at the time of submission.

259 **Additional Information**

260 Supplementary Information is available for this paper.

261 Correspondence and requests for materials should be addressed to Ugur Sahin.

262 **Materials and Methods**

263 **Clinical trial design**

264 Study BNT162-01 (NCT04380701) is an ongoing, first-in-human, Phase 1/2, open-label dose-ranging
265 clinical trial to assess the safety, tolerability, and immunogenicity of ascending dose levels of various
266 intramuscularly administered BNT162 mRNA vaccine candidates in healthy men and non-pregnant
267 women 18 to 55 years (amended to add 56 -85 of age) of age. Key exclusion criteria included previous
268 clinical or microbiological diagnosis of COVID-19; receipt of medications to prevent COVID-19;
269 previous vaccination with any coronavirus vaccine; a positive serological test for SARS-CoV-2 IgM
270 and/or IgG; and a SARS-CoV-2 NAAT-positive nasal swab; those with increased risk for severe
271 COVID-19; and immunocompromised individuals. The primary endpoints of the study are safety and
272 immunogenicity.

273 In the part of the study reported here, five dose levels (1 µg, 10 µg, 30 µg, 50 µg or 60 µg) of the
274 BNT162b1 candidate were assessed at one site in Germany with 12 healthy participants per dose level
275 in a dose-escalation/de-escalation design. Sentinel dosing was performed in each dose-escalation cohort.
276 Progression in that cohort and dose escalation required data review by a safety review committee.
277 Participants received a BNT162b1 prime dose on Day 1, and a boost dose on Day 22±2. Serum for
278 antibody assays was obtained on Day 1 (pre-prime), 8±1 (post-prime), 22±2 (pre-boost), 29±3 and 43±4
279 (post-boost). PBMCs for T cell studies were obtained on Day 1 (pre-prime) and 29±3 (post-boost).
280 Tolerability was assessed by patient diary. One subject of the 10 µg, and one subject of the 50 µg dose
281 cohort left the study prior to the boosting immunisation due to withdrawal of consent and private
282 reasons.

283 The presented data comprise the BNT162b1-immunised cohorts only and are based on a preliminary
284 analysis with a data extraction date of 13 July 2020, focused on analysis of vaccine-induced
285 immunogenicity (secondary endpoint) descriptively summarised at the various time points and on
286 reactogenicity. All participants with data available were included in the immunogenicity analyses.

287 The trial was carried out in Germany in accordance with the Declaration of Helsinki and Good Clinical
288 Practice Guidelines and with approval by an independent ethics committee (Ethik-Kommission of the
289 Landesärztekammer Baden-Württemberg, Stuttgart, Germany) and the competent regulatory authority
290 (Paul-Ehrlich Institute, Langen, Germany). All participants provided written informed consent.

291 **Manufacturing of RNA.**

292 BNT162b1 incorporates a Good Manufacturing Practice (GMP)-grade mRNA drug substance that
293 encodes the trimerized SARS-CoV-2 spike glycoprotein RBD antigen. The RNA is generated from a
294 DNA template by *in vitro* transcription in the presence of 1-methylpseudouridine-5'-triphosphate
295 (m¹YTP; Thermo Fisher Scientific) instead of uridine-5'-triphosphate (UTP). Capping is performed co-
296 transcriptionally using a trinucleotide cap 1 analogue ((m₂^{7,3'-O})Gppp(m^{2'-O})ApG; TriLink). The antigen-

297 encoding RNA contains sequence elements that increase RNA stability and translation efficiency in
298 human dendritic cells^{13,14}. The mRNA is formulated with lipids to obtain the RNA-LNP drug product.
299 The vaccine was transported and supplied as a buffered-liquid solution for IM injection and was stored
300 at -80 °C.

301 **Proteins and peptides.**

302 A pool of 15-mer peptides overlapping by 11 amino acids and covering the whole sequence of the
303 BNT162b1-encoded SARS-CoV-2 RBD, was used for *ex vivo* stimulation of PBMCs for flow
304 cytometry, IFN γ ELISpot and cytokine profiling. CEF (CMV, EBV, influenza virus; HLA class I epitope
305 peptide pool) and CEFT (CMV, EBV, influenza virus, tetanus toxoid; HLA class II epitope peptide
306 pool) (both JPT Peptide Technologies) were used as controls for general T-cell reactivity.

307 **Human convalescent sera and PBMC panel.**

308 Human SARS-CoV-2 infection/COVID-19 convalescent sera ($n=38$) were drawn from donors 18-83
309 years of age at least 14 days after PCR-confirmed diagnosis and at a time when the participants were
310 asymptomatic. Serum donors had symptomatic infections ($n=35$), or had been hospitalized ($n=1$). Sera
311 were obtained from Sanguine Biosciences (Sherman Oaks, CA), the MT Group (Van Nuys, CA) and
312 Pfizer Occupational Health and Wellness (Pearl River, NY). Human SARS-CoV-2 infection/COVID-
313 19 convalescent PBMC samples ($n=6$) were collected from donors 41-79 years of age 45-59 days after
314 PCR-confirmed diagnosis when donors were asymptomatic. PBMC donors had asymptomatic/mild
315 infections ($n= 4$; clinical score 1 and 2) or had been hospitalized ($n=2$; clinical score 4 and 5). Blood
316 samples were obtained from the Frankfurt University Hospital (Germany).

317 **Cell culture and primary cell isolation.**

318 Vero cells (ATCC CCL-81) and Vero E6 cells (ATCC CRL-1586) were cultured in Dulbecco's
319 modified Eagle's medium (DMEM) with GlutaMAX™ (Gibco) supplemented with 10% fetal bovine
320 serum (FBS) (Sigma-Aldrich). Cell lines were tested for mycoplasma contamination after receipt and
321 before expansion and cryopreservation. Peripheral blood mononuclear cells (PBMCs) were isolated by
322 Ficoll-Hypaque (Amersham Biosciences) density gradient centrifugation and cryopreserved prior to
323 subsequent analysis.

324 **RBD binding IgG antibody assay.**

325 A recombinant SARS-CoV-2 RBD containing a C-terminal Avitag™ (Acro Biosystems) was bound to
326 streptavidin-coated Luminex microspheres. Heat-inactivated participant sera were diluted 1:500,
327 1:5,000, and 1:50,000. Following an overnight incubation at 2-8 °C while shaking, plates were washed
328 in a solution containing 0.05% Tween-20. A secondary fluorescently labelled goat anti-human
329 polyclonal antibody (Jackson Labs) was added for 90 minutes at room temperature while shaking, before
330 plates were washed once more in a solution containing 0.05% Tween-20. Data were captured as median
331 fluorescent intensities (MFIs) using a Bioplex200 system (Bio-Rad) and converted to U/mL antibody

332 concentrations using a reference standard curve (reference standard composed of a pool of five
333 convalescent serum samples obtained >14 days post-COVID-19 PCR diagnosis and diluted sequentially
334 in antibody-depleted human serum) with arbitrary assigned concentrations of 100 U/mL and accounting
335 for the serum dilution factor. Three dilutions are used to increase the likelihood that at least one result
336 for any sample will fall within the useable range of the standard curve. Assay results were reported in
337 U/mL of IgG. The final assay results are expressed as the geometric mean concentration of all sample
338 dilutions that produced a valid assay result within the assay range.

339 **SARS-CoV-2 neutralisation assay.**

340 The neutralisation assay used a previously described strain of SARS-CoV-2 (USA_WA1/2020) that had
341 been rescued by reverse genetics and engineered by the insertion of an mNeonGreen (mNG) gene into
342 open reading frame 7 of the viral genome²⁹. This reporter virus generates similar plaque morphologies
343 and indistinguishable growth curves from wild-type virus. Viral master stocks (2×10^7 PFU/mL) were
344 grown in Vero E6 cells as previously described²⁹. With patient convalescent sera, the fluorescent
345 neutralisation assay produced comparable results to the conventional plaque reduction neutralisation
346 assay³⁰. Serial dilutions of heat-inactivated sera were incubated with the reporter virus (2×10^4 PFU per
347 well to yield approximately a 10-30% infection rate of the Vero CCL81 monolayer) for 1 hour at 37 °C
348 before inoculating Vero CCL81 cell monolayers (targeted to have 8,000 to 15,000 cells per well) in 96
349 -well plates to allow accurate quantification of infected cells. Total cell counts per well were enumerated
350 by nuclear stain (Hoechst 33342) and fluorescent virally infected foci were detected 16-24 hours after
351 inoculation with a Cytation 7 Cell Imaging Multi-Mode Reader (BioTek) with Gen5 Image Prime
352 version 3.09. Titers were calculated in GraphPad Prism version 8.4.2 by generating a 4-parameter (4PL)
353 logistical fit of the percent neutralisation at each serial serum dilution. The 50% neutralisation titre
354 (VNT₅₀) was reported as the interpolated reciprocal of the dilution yielding a 50% reduction in
355 fluorescent viral foci.

356 **VSV-SARS-CoV-2 spike variant pseudovirus neutralisation assay.**

357 Vesicular stomatitis virus (VSV)-SARS-CoV-2-S pseudoparticle generation and neutralisation assays
358 were performed as previously described²¹. Briefly, human codon optimized SARS-CoV-2 spike
359 (GenBank: MN908947.3) was synthesised (Genscript) and cloned into an expression plasmid. SARS-
360 CoV-2 complete genome sequences were downloaded from GISAID Nucleotide database
361 (<https://www.gisaid.org>). Sequences were curated and genetic diversity of the spike-encoding gene was
362 assessed across high quality genome sequences using custom pipelines. Amino acid substitutions were
363 cloned into the spike expression plasmid using site-directed mutagenesis. HEK293T cells (ATCC CRL-
364 3216) were seeded (culture medium: DMEM high glucose [Life Technologies] supplemented with 10%
365 heat-inactivated fetal bovine serum [FBS; Life Technologies] and penicillin/ptreptomycin/L-glutamine
366 [Life Technologies]) and transfected the following day with spike expression plasmid using
367 Lipofectamine LTX (Life Technologies) following the manufacturer's protocol. At 24 hours post-

368 transfection at 37 °C, cells were infected with the VSV Δ G:mNeon/VSV-G virus diluted in Opti-MEM
369 (Life Technologies) at a multiplicity of infection of 1. Cells were incubated 1 hour at 37 °C, washed to
370 remove residual input virus and overlaid with infection medium (DMEM high glucose supplemented
371 with 0.7% Low IgG BSA [Sigma], sodium pyruvate [Life Technologies] and 0.5% Gentamicin [Life
372 Technologies]). After 24 hours at 37 °C, the supernatant containing VSV-SARS-CoV-2-S
373 pseudoparticles was collected, centrifuged at 3000xg for 5 minutes to clarify and stored at -80 °C until
374 further use.

375 For pseudovirus neutralisation assays, Vero cells (ATCC CCL-81) were seeded in 96-well plates in
376 culture medium and allowed to reach approximately 85% confluence before use in the assay (24 hours
377 later). Sera were serially diluted 1:2 in infection medium starting with a 1:40 dilution. VSV-SARS-CoV-
378 2-S pseudoparticles were diluted 1:1 in infection medium for a fluorescent focus unit (ffu) count in the
379 assay of ~1000. Serum dilutions were mixed 1:1 with pseudoparticles for 30 minutes at room
380 temperature prior to addition to Vero cells and incubation at 37 °C for 24 hours. Supernatants were
381 removed and replaced with PBS (Gibco), and fluorescent foci were quantified using the SpectraMax i3
382 plate reader with MiniMax imaging cytometer (Molecular Devices). Neutralisation titers were
383 calculated in GraphPad Prism version 8.4.2 by generating a 4-parameter logistical (4PL) fit of the
384 percent neutralisation at each serial serum dilution. The 50% pseudovirus neutralisation titre (pVNT₅₀)
385 was reported as the interpolated reciprocal of the dilution yielding a 50% reduction in fluorescent viral
386 foci.

387 **IFN γ ELISpot.**

388 IFN γ ELISpot analysis was performed *ex vivo* (without further *in vitro* culturing for expansion) using
389 PBMCs depleted of CD4⁺ and enriched for CD8⁺ T cells (CD8⁺ effectors), or depleted of CD8⁺ and
390 enriched for CD4⁺ T cells (CD4⁺ effectors). Tests were performed in duplicate and with a positive
391 control (anti-CD3 monoclonal antibody CD3-2 [1:1,000; Mabtech]). Multiscreen filter plates (Merck
392 Millipore) pre-coated with IFN γ -specific antibodies (ELISpotPro kit, Mabtech) were washed with PBS
393 and blocked with X-VIVO 15 medium (Lonza) containing 2% human serum albumin (CSL-Behring)
394 for 1-5 hours. Per well, 3.3 x 10⁵ effector cells were stimulated for 16-20 hours with an overlapping
395 peptide pool representing the vaccine-encoded RBD. Bound IFN γ was visualized using a secondary
396 antibody directly conjugated with alkaline phosphatase followed by incubation with BCIP/NBT
397 substrate (ELISpotPro kit, Mabtech). Plates were scanned using an AID Classic Robot ELISPOT Reader
398 and analysed by ImmunoCapture V6.3 (Cellular Technology Limited) or AID ELISPOT 7.0 software
399 (AID Autoimmun Diagnostika). Spot counts were displayed as mean values of each duplicate. T-cell
400 responses stimulated by peptides were compared to effectors incubated with medium only as a negative
401 control using an in-house ELISpot data analysis tool (EDA), based on two statistical tests (distribution-

402 free resampling) according to Moodie et al.^{31,32}, to provide sensitivity while maintaining control over
403 false positives.

404 To account for varying sample quality reflected in the number of spots in response to anti-CD3 antibody
405 stimulation, a normalisation method was applied to enable direct comparison of spot counts/strength of
406 response between individuals. This dependency was modelled in a log-linear fashion with a Bayesian
407 model including a noise component (unpublished). For a robust normalization, each normalisation was
408 sampled 1000 times from the model and the median taken as normalized spot count value. Likelihood
409 of the model: $\log \lambda_E = \alpha \log \lambda_P + \log \beta_j + \sigma \varepsilon$, where λ_E is the normalized spot count of the sample, α
410 is a stable factor (normally distributed) common among all positive controls λ_P , β_j a sample j specific
411 component (normally distributed) and $\sigma \varepsilon$ is the noise component, of which σ is Cauchy distributed and
412 ε is Student's-t distributed. β_j ensures that each sample is treated as a different batch.

413 **Flow cytometry.**

414 Cytokine-producing T cells were identified by intracellular cytokine staining. PBMCs thawed and rested
415 for 4 hours in OpTmizer medium supplemented with 2 $\mu\text{g}/\text{mL}$ DNase I (Roche), were restimulated with
416 a peptide pool representing the vaccine-encoded SARS-CoV-2 RBD (2 $\mu\text{g}/\text{mL}/\text{peptide}$; JPT Peptide
417 Technologies) in the presence of GolgiPlug (BD) for 18 hours at 37 °C. Controls were treated with
418 DMSO-containing medium. Cells were stained for viability and surface markers in flow buffer (DPBS
419 [Gibco] supplemented with 2% FCS [Biochrom], 2 mM EDTA [Sigma-Aldrich]) for 20 minutes at 4 °C.
420 Afterwards, samples were fixed and permeabilized using the Cytotfix/Cytoperm kit according to
421 manufacturer's instructions (BD Biosciences). Intracellular staining was performed in Perm/Wash
422 buffer for 30 minutes at 4 °C. Samples were acquired on a FACS VERSE instrument (BD Biosciences)
423 and analysed with FlowJo software version 10.5.3 (FlowJo LLC, BD Biosciences). RBD-specific
424 cytokine production was corrected for background by subtraction of values obtained with DMSO-
425 containing medium. Negative values were set to zero. Cytokine production in Figure 4b was calculated
426 by summing up the fractions of all CD4⁺ T cells positive for either IFN γ , IL-2 or IL-4, setting this sum
427 to 100% and calculating the fraction of each specific cytokine-producing subset thereof.

428 **Cytokine profiling.**

429 Human PBMCs were restimulated for 48 hours with SARS-CoV-2 RBD peptide pool (2 $\mu\text{g}/\text{mL}$ final
430 concentration per peptide). Stimulation with DMSO-containing medium served as negative controls.
431 Concentrations of TNF, IL-1 β , IL-12p70, IL-4 and IL-5 in supernatants were determined using a bead-
432 based, 11-plex T_H1/T_H2 human ProcartaPlex immunoassay (Thermo Fisher Scientific) according to the
433 manufacturer's instructions. Fluorescence was measured with a Bioplex200 system (Bio-Rad) and
434 analysed with ProcartaPlex Analyst 1.0 software (Thermo Fisher Scientific). RBD-specific cytokine
435 production was corrected for background by subtraction of values obtained with DMSO-containing
436 medium. Negative values were set to zero.

437 **Data availability.**

438 The data that support the findings of this study are available from the corresponding author upon
439 reasonable request. Upon completion of this clinical trial, summary-level results will be made public
440 and shared in line with data sharing guidelines.

441 **References**

- 442 1. WHO. Coronavirus disease (COVID-19) Situation Report-161. *accessed June 30th* (2020).
- 443 2. Habibzadeh, P. & Stoneman, E. K. The Novel Coronavirus: A Bird's Eye View. *Int. J. Occup.*
444 *Environ. Med.* **11**, 65–71 (2020).
- 445 3. Petsch, B. *et al.* Protective efficacy of in vitro synthesized, specific mRNA vaccines against
446 influenza A virus infection. *Nat. Biotechnol.* **30**, 1210–6 (2012).
- 447 4. Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics - developing a new class of drugs.
448 *Nat. Rev. Drug Discov.* **13**, 759–780 (2014).
- 449 5. Pardi, N. *et al.* Zika virus protection by a single low-dose nucleoside-modified mRNA
450 vaccination. *Nature* (2017). doi:10.1038/nature21428
- 451 6. Pardi, N. *et al.* Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and
452 rhesus macaques. *Mol. Ther. - Nucleic Acids* **15**, 36–47 (2019).
- 453 7. Sahin, U. *et al.* An RNA vaccine drives immunity in checkpoint inhibitor-experienced
454 melanoma. *Nature Accepted* (2020).
- 455 8. Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New Vaccine Technologies to Combat
456 Outbreak Situations. *Front. Immunol.* **9**, (2018).
- 457 9. Pardi, N. *et al.* Expression kinetics of nucleoside-modified mRNA delivered in lipid
458 nanoparticles to mice by various routes. *J. Control. Release* **217**, 345–351 (2015).
- 459 10. Pardi, N. *et al.* Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin
460 stalk-specific antibodies. *Nat. Commun.* **9**, 3361 (2018).
- 461 11. Mulligan, M. J. *et al.* Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-
462 19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report.
463 *medRxiv Prepr. Serv. Heal. Sci.* (2020). doi:medRxiv: 10.1101/2020.06.30.20142570
- 464 12. Tai, W. *et al.* A recombinant receptor-binding domain of MERS-CoV in trimeric form protects
465 human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. *Virology*
466 **499**, 375–382 (2016).
- 467 13. Holtkamp, S. *et al.* Modification of antigen-encoding RNA increases stability, translational
468 efficacy, and T-cell stimulatory capacity of dendritic cells. *Blood* **108**, 4009–4017 (2006).
- 469 14. Orlandini von Niessen, A. G. *et al.* Improving mRNA-Based Therapeutic Gene Delivery by
470 Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. *Mol. Ther.* **27**, 824–
471 836 (2019).
- 472 15. Karikó, K. *et al.* Incorporation of pseudouridine into mRNA yields superior nonimmunogenic

- 473 vector with increased translational capacity and biological stability. *Mol. Ther.* **16**, 1833–40
474 (2008).
- 475 16. Tsai, M. Y. *et al.* Effect of influenza vaccine on markers of inflammation and lipid profile. *J.*
476 *Lab. Clin. Med.* **145**, 323–7 (2005).
- 477 17. Taylor, D. N. *et al.* Development of VAX128, a recombinant hemagglutinin (HA) influenza-
478 flagellin fusion vaccine with improved safety and immune response. *Vaccine* **30**, 5761–9 (2012).
- 479 18. Doener, F. *et al.* RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies
480 vaccine in a first-in-human trial. *Vaccine* **37**, 1819–1826 (2019).
- 481 19. Destexhe, E. *et al.* Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for
482 vaccine nonclinical safety studies. *J. Pharmacol. Toxicol. Methods* **68**, 367–73
- 483 20. Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly regulate
484 lymphocyte recirculation and cause transient blood lymphopenia. *Blood* **108**, 3253–61 (2006).
- 485 21. Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
486 escape seen with individual antibodies. *Science* eabd0831 (2020). doi:10.1126/science.abd0831
- 487 22. Zhang, L. *et al.* The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and
488 increases infectivity. *bioRxiv Prepr. Serv. Biol.* (2020). doi:bioRxiv:
489 10.1101/2020.06.12.148726
- 490 23. Sette, A. *et al.* Selective CD4⁺ T cell help for antibody responses to a large viral pathogen:
491 deterministic linkage of specificities. *Immunity* **28**, 847–58 (2008).
- 492 24. Vabret, N. *et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**, 910–
493 941 (2020).
- 494 25. Sainz, B., Mossel, E. C., Peters, C. J. & Garry, R. F. Interferon-beta and interferon-gamma
495 synergistically inhibit the replication of severe acute respiratory syndrome-associated
496 coronavirus (SARS-CoV). *Virology* **329**, 11–7 (2004).
- 497 26. Chong, W. P. *et al.* The interferon gamma gene polymorphism +874 A/T is associated with
498 severe acute respiratory syndrome. *BMC Infect. Dis.* **6**, 82 (2006).
- 499 27. Ng, O.-W. *et al.* Memory T cell responses targeting the SARS coronavirus persist up to 11 years
500 post-infection. *Vaccine* **34**, 2008–14 (2016).
- 501 28. Gallais, F. *et al.* Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response
502 without Seroconversion. *medRxiv Prepr. Serv. Heal. Sci.* (2020). doi:medRxiv:
503 10.1101/2020.06.21.20132449
- 504 29. Xie, X. *et al.* An Infectious cDNA Clone of SARS-CoV-2. *Cell Host Microbe* **27**, 841-848.e3
505 (2020).

- 506 30. Muruato, A. E. *et al.* A high-throughput neutralizing antibody assay for COVID-19 diagnosis
507 and vaccine evaluation. *bioRxiv Prepr. Serv. Biol.* Accepted at Nat Commun. (2020). doi:bioRxiv:
508 10.1101/2020.05.21.109546
- 509 31. Moodie, Z., Huang, Y., Gu, L., Hural, J. & Self, S. G. Statistical positivity criteria for the analysis
510 of ELISpot assay data in HIV-1 vaccine trials. *J. Immunol. Methods* **315**, 121–32 (2006).
- 511 32. Moodie, Z. *et al.* Response definition criteria for ELISPOT assays revisited. *Cancer Immunol.*
512 *Immunother.* **59**, 1489–501 (2010).
- 513 33. U.S. Department of Health and Human Services, Administration, F. and D. & Research, C. for
514 B. E. and. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in
515 preventive vaccine clinical trials. (2007). Available at: [https://www.fda.gov/regulatory-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)
516 [information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)
517 [adolescent-volunteers-enrolled-preventive-vaccine-clinical](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical).
- 518




Figure 1 | BNT162b1-induced IgG concentrations.

Participants were immunised with BNT162b1 on Days 1 (all dose levels) and 22 (all dose levels except 60 µg) ($n=12$ per group, from Day 22 on $n=11$ for the 10 µg and 50 µg cohort). Sera were obtained on Day 1 (Pre prime) and on day 8, 22 (pre boost), 29 and 43. Pre-dose responses across all dose levels were combined. Human COVID-19 convalescent sera (HCS, $n=38$) were obtained at least 14 days after PCR-confirmed diagnosis and at a time when the donors were no longer symptomatic. For RBD-binding IgG concentrations below the lower limit of quantification (LLOQ = 1.15), LLOQ/2 values were plotted. Arrowheads indicate vaccination. Chequered bars indicate that no boost immunisation was performed. Values above bars are geometric means with 95% confidence intervals. At the time of submission, Day 43 data were pending for all participants of the 60 µg cohort.




Figure 2 | BNT162b1-induced virus neutralisation titers.

The vaccination schedule and serum sampling are described in Figure 1. **a**, SARS-CoV-2 50% neutralisation titers (VNT_{50}) in immunised participants and COVID-19 convalescent patients (HCS). For values below the lower limit of quantification (LLOQ) = 20, LLOQ/2 values were plotted. Arrowheads indicate days of immunisation. Chequered bars indicate that no boost immunisation was performed. Geometric mean titers (values above bars) with 95% confidence interval are shown. At the time of submission, Day 43 data were pending for all participants of the 60 μ g cohort, **b**, Correlation of RBD-binding IgG geometric mean concentrations (GMC) (as in Figure 1) with VNT_{50} on Day 29 (all evaluable participant sera). Nonparametric Spearman correlation. **c**, Pseudovirus 50% neutralisation titers ($pVNT_{50}$) across a pseudovirus panel displaying 17 SARS-CoV-2 spike protein variants including 16 RBD mutants and the dominant spike protein variant D614G (dose levels 10, 30 and 50 μ g, $n=1-2$ each; Day 29). Lower limit of quantification (LLOQ) = 40. Geometric mean titers are displayed.




Figure 3 | Frequency and magnitude of BNT162b1-induced CD4⁺ and CD8⁺ T-cell responses.

The vaccination schedule is described in Figure 1. PBMCs obtained on Day 1 (Prevaccination) and on Day 29 (Postvaccination, 7 days after boost) (1 and 50 μ g, $n=8$ each; 10 and 30 μ g, $n=10$ each) were enriched for CD4⁺ or CD8⁺ T cell effectors and separately stimulated over night with an overlapping peptide pool representing the vaccine-encoded RBD for assessment in direct *ex vivo* IFN γ ELISpot. Common pathogen T-cell epitope pools CEF (CMV, EBV, influenza virus HLA class I epitopes) and CEFT (CMV, EBV, influenza virus, tetanus toxoid HLA class II epitopes) served to assess general T-cell reactivity, cell culture medium served as negative control. Each dot represents the normalized mean spot count from duplicate wells for one study participant, after subtraction of the medium-only control. **a**, Ratios above post-vaccination data points are the number of participants with detectable CD4⁺ or CD8⁺ T cell response within the total number of tested participants per dose cohort. **b**, Exemplary CD4⁺ and CD8⁺ ELISpot of a 10- μ g cohort subject. **c**, RBD-specific CD4⁺ and CD8⁺ T cell responses in all prime/boost vaccinated participants and their baseline CEFT- and CEF-specific T-cell responses. Nonparametric Spearman correlation.






Figure 4 | Cytokine polarisation of BNT162b1-induced T cells.

The vaccination schedule and PBMC sampling are described in Figure 3. PBMCs of vaccinees and COVID-19 recovered donors (HCS $n=6$; in (c)) were stimulated over night with an overlapping peptide pool representing the vaccine-encoded RBD and analysed by flow cytometry (a-c) and bead-based immunoassay (d). **a**, Exemplary pseudocolor flow cytometry plots of cytokine-producing $CD4^+$ and $CD8^+$ T cells from a 10- μ g cohort participant. **b**, RBD-specific $CD4^+$ T cells producing the indicated cytokine⁺ as a fraction of total cytokine-producing RBD-specific $CD4^+$ T cells. **c**, RBD-specific $CD8^+$ (left) or $CD4^+$ (right) T cells producing the indicated cytokine as a fraction of total circulating T cells of the same subset. One $CD4^+$ non-responder ($<0.02\%$ total cytokine producing T cells) from the 30- μ g cohort was excluded in (b). Values above data points are the mean fractions across all dose cohorts. **d**, PBMCs from the 50- μ g cohort. Each dot represents the mean from duplicate wells subtracted by the DMSO control for one study participant. Lower limits of quantification (LLOQ) were 6.3 pg/mL for TNF, 2.5 pg/mL for IL-1 β , 7.6 pg/mL for IL-12p70, 11.4 pg/mL for IL-4 and 5.3 pg/mL for IL-5. Mean (b).




Extended Data Figure 1 | Schedule of vaccination and assessment.

Study participants received a prime immunisation with BNT162b1 on Day 1 (all dose levels), and a boost immunisation on Day 22±2 (all dose levels except 60 µg). Serum was obtained on Day 1 (pre-prime), 8±1 (post-prime), 22±2 (pre-boost), 29±3 and 43±4 (post-boost). PBMCs were obtained on Day 1 (pre-prime) and 29±3 (post-boost).




Extended Data Figure 2 | Solicited adverse events.

Number of participants with local (a) or systemic AEs (b). Participants were immunised with BNT162b1 on Days 1 (all dose levels) and 22 (all dose levels except 60 µg) ($n=12$ per group; $n=11$ for 10 µg and 50 µg cohort from Day 22 on; discontinuation of patients due to non-vaccine related reasons; missing data points are indicated). As per protocol AEs were recorded up to 7 days after each immunisation (Days 1-7 and 22-28), and for some participants 1-2 additional days of follow-up were available. Grading of adverse events was performed according to FDA recommendations³³.



Extended Data Figure 3 | Pharmacodynamic markers.

Participants were immunised with BNT162b1 on Days 1 (all dose levels) and 22 (all dose levels except 60 µg). **a**, Kinetics of C-reactive protein (CRP) level and **b**, Kinetics of lymphocyte counts. Dotted lines indicate upper and lower limit of reference range. For values below the lower limit of quantification (LLOQ = 0.3), LLOQ/2 values were plotted (a).



Extended Data Figure 4 | Correlation of antibody and T-cell responses.

Participants were immunised with BNT162b1 on Days 1 (all dose levels) and 22 (all dose levels except 60 μ g). **a**, Correlation of RBD-specific IgG responses (from Figure 1a) with CD4⁺ T-cell responses on Day 29 (1 and 50 μ g, $n=8$ each; 10 and 30 μ g, $n=10$ each). Nonparametric Spearman correlation. **b**, Correlation of CD4⁺ with CD8⁺ T-cell responses (as in Figure 3) from Day 29 in dose cohorts 10 to 50 μ g. Parametric Pearson correlation. **c**, Correlation of RBD-specific IgG responses (as in Figure 1a) with CD8⁺ T-cell responses (as in Figure 3) on Day 29. Nonparametric Spearman correlation. **d**, Correlation of VNT₅₀ (as in Figure 2a) with CD4⁺ T-cell responses (as in Figure 3) in dose cohorts 10 to 50 μ g (1 and 50 μ g, $n=8$ each; 10 and 30 μ g, $n=10$ each).

Extended Data Table 1 | Subject disposition and analysis sets.

Antibody analysis: Values indicate number of participants for whom virus neutralisation assays and RBD binding IgG antibody assays were performed. T-cell analysis: Values indicate number of participants for whom IFN γ ELISpot and flow cytometry (values in parentheses) was performed. N/A: Samples not yet available.

Cohort	BNT162b1		Antibody analysis					T-cell analysis	
	Prime	Boost	Day 1	Day 8 \pm 1	Day 22 \pm 2	Day 29 \pm 3	Day 43 \pm 4	Day 1	Day 29 \pm 3
1 μ g	12	12	12	12	12	12	12	8	8
10 μ g	12	11	12	12	12	11	11	10 (6)	10 (6)
30 μ g	12	12	12	12	12	12	12	10 (7)	10 (7)
50 μ g	12	11	12	12	12	11	11	8 (5)	8 (5)
60 μ g	12	N/A	12	12	11	12	N/A	N/A	N/A